Guggenheim analyst Vamil Divan downgraded Keros Therapeutics (KROS) to Neutral from Buy.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics price target lowered to $44 from $77 at Scotiabank
- Keros Therapeutics price target raised to $28 from $11 at Wells Fargo
- Keros Therapeutics price target lowered to $47 from $100 at H.C. Wainwright
- BofA cuts Keros target to $33, says ‘story still intact’ despite ‘setback’
- Keros Therapeutics downgraded to Hold from Buy at TD Cowen